NCT05331014View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

PHASE3CompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions

DyslipidemiaHypertension

Interventions

DRUG

LivaloVA

For 8 weeks(PO, QD)

DRUG

LivaloV

For 8 weeks(PO, QD)

DRUG

VA

For 8 weeks(PO, QD)

Trial Locations (1)

134-701

Gangdong Sacred Heart Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY